by Antisense and RNAi therapeutics are nucleic acid-based drugs that are designed to specifically target messenger RNA (mRNA) in order to reduce or silence disease-causing genes. Antisense oligonucleotides function by binding to their complementary mRNA sequences, thereby preventing translation and protein expression. RNA interference (RNAi) technology utilizes small interfering RNAs (siRNAs) that are designed to degrade specific mRNAs. Both approaches provide promise for treating various genetic disorders that were previously untreatable. The global antisense and RNAi therapeutics market is witnessing rapid growth driven by the rise in prevalence of various genetic and inherited disorders worldwide. According to statistics, around 10% of human diseases are caused due to genetic defects, highlighting the need for advanced treatment options for conditions such as Pompe disease, Huntington’s disease, and Duchenne muscular dystrophy. The increasing R&D investment by key players to expand clinical trial pipelines of nucleic acid-based drugs is further fueling the market growth. The global Antisense & RNAi Therapeutics Market is estimated to be valued at US$ 6.38 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the global antisense & RNAi therapeutics market is the rise in clinical trial activity. There has been a steady increase in the number of antisense and RNAi therapeutics entering phase I, II, and III clinical trials in recent years. For instance, Ionis Pharmaceuticals currently has over 20 antisense drug candidates in clinical trials targeting various genetic diseases. Similarly, Alnylam Pharmaceuticals has five RNAi therapeutic programs in late-stage clinical testing. Another important trend is the widening of potential therapeutic applications beyond genetic disorders. Research is ongoing to evaluate the efficacy of antisense and RNAi technologies in treating infectious diseases, cancer, and neurodegenerative conditions utilizing their gene silencing properties. This could prove highly lucrative for market players as it opens up new avenues for product development.
Porter’s Analysis
Threat of new entrants: Low barriers of entry due to high capital requirements to develop new therapeutics. Biosimilars pose threat.
Bargaining power of buyers: Large pharmaceutical companies have high bargaining power over smaller biotech firms and academic organizations.
Bargaining power of suppliers: Few players dominate the raw material supply indicating high power. High development costs act as a barrier.
Threat of new substitutes: Emergence of newer drug delivery platforms pose substitutes threat.
Competitive rivalry: Intense competition due to presence of large players and biosimilars. Firms rely on collaborations and partnerships.
Key Takeaways
The global Antisense & RNAi Therapeutics market size is expected to witness high growth. The market size is projected to reach US$ 6.38 Bn by 2024 registering a CAGR of 18% during the forecast period.
North America is expected to dominate the market during the forecast period. Increased R&D investments, growing biotechnology industry and government support drive regional market growth. The presence of key market players and technological innovations contributes to market expansion.
Key players
operating in the Antisense & RNAi Therapeutics market are Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc., Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma. Leading players focus on collaborations and license agreements to strengthen product pipelines and market presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
